Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity

Aims/Introduction:  Recently, glucagon‐like peptide‐1 (GLP‐1) receptor agonists of liraglutide have become available in Japan. It has not yet been clarified what clinical parameters could discriminate liraglutide‐effective patients from liraglutide‐ineffective patients.

[1]  Weiping Jia,et al.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.

[2]  Y. Seino,et al.  Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[3]  Y. Seino,et al.  Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. , 2004, Metabolism: clinical and experimental.

[4]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[5]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[6]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[7]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[8]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[9]  Y. Seino,et al.  Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes , 2010, Current medical research and opinion.

[10]  W. Uhl,et al.  Functional assessment of pancreatic beta-cell area in humans , 2009 .

[11]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[12]  Xiao Wang,et al.  Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation , 2009, Diabetes/metabolism research and reviews.

[13]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[14]  Yuichiro Yamada,et al.  Factors responsible for age-related elevation in fasting plasma glucose: a cross-sectional study in Japanese men. , 2008, Metabolism: clinical and experimental.

[15]  W. Uhl,et al.  Functional Assessment of Pancreatic β-Cell Area in Humans , 2009, Diabetes.